Norbert Hilf

TL;DR: Among six predefined populations of myeloid-derived suppressor cells, two were prognostic for overall survival, and among over 300 serum biomarkers, apolipoprotein A-I (APOA1) and chemokine (C-C motif) ligand 17 (CCL17) as being predictive for both immune response to IMA901 and overall survival are identified.

TL;DR: In a phase I trial, highly individualized peptide vaccines against unmutated tumour antigens and neoepitopes elicited sustained responses in CD8+ and CD4+ T cells, respectively, in patients with newly diagnosed glioblastoma.

TL;DR: The results provide the molecular basis for understanding the Gp96-mediated activation of antigen-presenting cells by describing the simultaneous stimulation of the innate and adaptive immune system.

TL;DR: It is described that gp96 mediates maturation of DC as determined by up‐regulation of MHC class II and CD86 molecules, secretion of the cytokines IL‐12 and TNF‐α and enhanced T cell stimulatory capacity.

TL;DR: It is demonstrated that for CTL activation by gp96-chaperoned peptides, specific receptor-mediated uptake of gp96 by antigen-presenting cells (APCs) is required and that in both humans and mice, only professional APCs like dendritic cells, macrophages, and B cells, but not T cells, are able to bind gp96.